PG18 A COST-EFFECTIVENESS EVALUATION-RETREATMENT WITH PEGYLATED INTERFERON ALFA 2B PLUS RIBAVIRIN IN HEPATITIS C PATIENTSWHO HAVE PREVIOUSLY RECEIVED INTERFERON-BASED THERAPY AND FAILED TO ATTAIN A SUSTAINED VIROLOGICAL RESPONSE
Abstract
Authors
CJ Gibbons J Morris AK OSullivan